UNSPSC 51431611: Gallopamil hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C28H40N2O5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VT4VR32A0T, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-isopropyl-2-(3,4,5-trimethoxyphenyl)valeronitrile but more generally known as gallopamil hydrochloride, which bears US NIH Compound Identifier 1234. European Medicines Agency schedules Gallopamil hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02309MIG.

UNSPSC 51431611 Gallopamil hydrochloride is a Commodity code designating a specific pharmaceutical active ingredient used in emergency medical response and clinical settings. State and local government procurement under this code centers on acquiring finished pharmaceutical products—vials, injections, and other dosage forms—for use by fire rescue departments, health agencies, and hospital systems rather than acquiring the raw chemical compound itself. The issuing bodies include municipal fire departments, state health and human services commissions, and cooperative purchasing alliances representing multiple jurisdictions. Work solicited under the code involves supplying medications that meet FDA standards, maintain specified expiration dates and shelf-life requirements, comply with Good Manufacturing Practices and Drug Supply Chain Security Act standards, and include comprehensive Safety Data Sheets and accessibility documentation. Vendors must manage product logistics including timely delivery, expired-material replacement protocols, and compatibility with authorized pharmaceutical wholesaler networks.

Recent opportunities show activity concentrated in the South and Upper Midwest. The City of Tampa issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue) with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00 under a Small Local Business Enterprise sheltered market set-aside. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline to establish multi-award generic pharmaceutical contracts distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through designated wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and accept a 3 percent administrative fee. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 as exploratory market intelligence on direct-to-manufacturer prescription programs, signaling potential future formal solicitation but carrying no budget or binding timeline at the information-gathering stage.